Our weekly market outlook, straight to your inbox.

Get the Schaeffer’s edge every Monday.

 

 
 
 
X

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

Apr 8, 2016, 10:01 AM by Karee Venema
Today's stocks to watch in the news include Intercept Pharmaceuticals Inc (ICPT), Anavex Life Sciences Corp (AVXL), and Depomed Inc (DEPO)
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
  

ABOUTus


Schaeffer's Investment Research, Inc. has been providing stock market publications, market recommendation services and stock option education since its inception in 1981 by founder and CEO, Bernie Schaeffer.  Headquartered in Cincinnati, OH, Schaeffer's Investment Research has become a leading and trusted source of research and analysis for individual investors and major financial media outlets.

TRADINGpublications


|FROM THE TOP
by bernie schaeffer
Because today's investor is aware of the benefits of options trading, options investing is shifting to mainstream popularity, Bernie Schaeffer, author of The Option Advisor, continues to provide accessible, sophisticated analysis and research of options trading for every investor in his weekly and monthly columns.

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
From The Top

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
|MONDAY MORNING OUTLOOK
by todd salamone
Todd Salamone is the Senior VP of Research and author of the Monday Morning Outlook. To receive your weekly column, subscribe to Monday Morning Outlook.

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
|INDICATOR OF THE WEEK
by rocky white
Rocky White is a quantitative analyst at Schaeffer’s Research and author of Indicator of the Week. To get more tips on options indicators, subscribe to any of our free publications.

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
Weekly Publications

Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

TRADING SERVICES | FEATUREDproducts


By E.W. from Kentucky
I have tried many different programs and services in the past with mix results. Stop your search here. Schaeffer's Investment Research is bottom line the most professional, experienced, and confidence building investment research firm. After trying an initial package I spoke with my account manager, Nathane Sharp, who helped me tailor my trading style to the right package. His professionalism and experienced approach matched me perfectly. The track record speaks for itself and the money back guarantee sells you. I have found my investment firm for the rest of my trading career.
Options trading made simple.
Schaeffer's Investment Research, Inc. is dedicated to providing subscribers advantages in options trading and investing.  Our independent market research services create profitable opportunities for investors at every level.
FREE NEWS & ALERTS

Get the best of Schaeffer's financial market news every morning directly to your inbox.

Find Out How

TRENDINGnews


Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

OPTIONSnews


Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

EDITOR'Spicks


Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

ANALYSTupdates


Buzz Stocks: Intercept Pharmaceuticals Inc, Anavex Life Sciences Corp, and Depomed Inc

by Karee Venema | Apr 08, 2016
Stocks are signaling a positive start this morning, as oil prices bounce on supportive comments from Fed Chair Janet Yellen. Meanwhile, pharmaceutical stocks are in focus today, with Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Anavex Life Sciences Corp (NASDAQ:AVXL), and Depomed Inc (NASDAQ:DEPO) all in the news.

  • Just days after the Food and Drug Administration (FDA) waxed optimistic on ICPT's cirrhosis treatment, an FDA panel unanimously voted in support of accelerated approval of the drug, obeticholic acid (OCA). Nevertheless, a bearish brokerage note from Morgan Stanley -- which lowered its rating on ICPT to "underweight" from "equal weight" and its price target to $80 from $100 -- has sent the shares of Intercept Pharmaceuticals Inc 5% lower to $155.74, paring their week-to-date advance to 19%. Short sellers are likely cheering today's reversal, considering 22% of ICPT's float is sold short, or 7.8 times the stock's average daily volume.

  • The FDA also weighed in on AVXL, granting orphan status to its frontotemporal dementia (FTD) drug -- sending the shares up 11.3% out of the gate to $5.92, and on track for their first close north of their 120-day moving average since Jan. 4. Longer term, AVXL is off 60% from its Nov. 3 four-year high of $14.84, and short sellers have been ramping up their bearish exposure. In fact, short interest is up nearly 43% from the Nov. 15 report, and now accounts for a healthy 10.1% of Anavex Life Sciences Corp's available float.

  • Starboard Value LP is attempting to pull a Yahoo! Inc. (NASDAQ:YHOO) on DEPO, with the activist hedge fund unveiling a 6.8% stake in the company and revealing plans to make six board nominations. Starboard said it is concerned over a "series of shareholder-unfriendly steps" taken by DEPO, including last year's rejection of Horizon Pharma PLC's (NASDAQ:HZNP) hostile-takeover attempt. Shares of DEPO have surged 15.7% out of the gate to $17.35 -- and north of their 30-week moving average in intraday action for the first time since mid-September. Today's bull gap may have short sellers on edge. Short interest on Depomed Inc surged 12.2% in the last two reporting periods, and now accounts for more than 23% of the stock's available float.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Partnercenter


OURfans